VC/PE

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

BioXconomy presents the Asia biopharma and healthcare dealmaking and financing news for the week ending 8 November.

byRichard Daverman

Nov 18, 2024

|

1 Min Read

Panelists Anta Gkelou Partner, Sofinnova Partners; Bobby Soni CIO, BioInnovation Institute; Renee Lucander CEO, Calliditas Therapeutics

Successful mentorship between investors and CEOs hangs on respect Successful mentorship between investors and CEOs hangs on respect

Nov 15, 2024

1 Min Read

Europe’s adversity to risk is why the US is ahead, say experts Europe’s adversity to risk is why the US is ahead

byMillie Nelson

Nov 5, 2024

1 Min Read

Eyes on Asia: Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

byRichard Daverman

Nov 5, 2024

1 Min Read

Picture with women's health written on a card in pink

Call for specific female health funding to tackle biotech finance gender gap Call for specific female health funding to tackle biotech finance gender gap

byMillie Nelson

Oct 30, 2024

1 Min Read

What’s your secret sauce? VC’s on what makes a compelling pitch VC’s on what makes a compelling pitch

byMillie Nelson

Oct 24, 2024

1 Min Read

'Is the worst behind us?' Financial expert talks biotech funding

'Is the worst behind us?' Financial expert talks biotech funding

byBrian Scanlan, Dan Stanton

Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?

News from Sanofi, Bayer, AZ plus the return of VC?

byRichard Daverman

Overhead view of business people working and funding

$325 million Series C funding in its Arsenal (Biosciences)

$325 million Series C funding in its Arsenal (Biosciences)

byMillie Nelson

Plenary at BIO-Europe in Munich

How industry trends are evolving biotech innovation in 2023

2023 industry trends that helped evolve biotech innovation

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

byRichard Daverman

GSK, Novartis, Calliditas among winners at LSX Awards

GSK, Novartis, Calliditas among winners at LSX Awards

byMillie Nelson

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.